Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator: Sarbajit Mukherjee, MD, MS Condition: Esophageal or gastroesophageal junction adenocarcinoma Institutions: Roswell Park
Search Results
Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator: Sarbajit Mukherjee, MD, MS Condition: Esophageal or gastroesophageal junction adenocarcinoma Institutions: Roswell Park
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator
Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator: Sarbajit Mukherjee, MD, MS Condition: Esophageal or gastroesophageal junction adenocarcinoma Institutions: Roswell Park
Jean L. Grem
C-10 evaluated bolus and infusional 5-FU, leucovorin, and oxaliplatin (FOLFOX6) plus bevacizumab for patients with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor. 11 The results indicated that patients with
Crystal S. Denlinger and Andrea M. Barsevick
Edited by Kerrin G. Robinson
Fleming T Macdonald J . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma . N Engl J Med 1990 ; 322 : 352 – 358 . 7 de Gramont A Boni C Navarro M . Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy
Mary F. Mulcahy and Al B. Benson III
phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines . Ann Oncol 1996 ; 7 : 95 – 98 . 11 Levi F Perpoint B Garufi C
-roshevsky@northwestern.edu ClinicalTrials.gov Identifier: NCT01008917 Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial With Predictive Molecular Correlates Principal Investigator: Nikhil I. Khushalani, MD Condition
Wells A. Messersmith
treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab
